Stocks of Calidi Biotherapeutics Inc (AMEX:CLDI) traded higher last session on Wall Street, down -1.21% to $0.57.
CLDI stock price is now 46.95% away from the 50-day moving average and -40.33% away from the 200-day moving average. The market capitalization of the company currently stands at $19.75M.
With the price target of $11, H.C. Wainwright recently initiated with Buy rating for Calidi Biotherapeutics Inc (AMEX: CLDI). On October 09, 2023, Robert W. Baird recently initiated its ‘Outperform’ rating on the stock quoting a target price of $9
In other news, Camaisa Allan, CEO and Chairman of the Board sold 10,000 shares of the company’s stock on Dec 17 ’24. The stock was sold for $16,200 at an average price of $1.62. Upon completion of the transaction, the CEO and Chairman of the Board now directly owns 66,712 shares in the company, valued at $38025.84. A total of 6.57% of the company’s stock is owned by insiders.
During the past 12 months, Calidi Biotherapeutics Inc has had a low of $0.20 and a high of $3.89. As of last week, the company has a debt-to-equity ratio of 0.68, a current ratio of 2.12, and a quick ratio of 2.12. The fifty day moving average price for CLDI is $0.3875 and a two-hundred day moving average price translates $0.9616 for the stock.
The latest earnings results from Calidi Biotherapeutics Inc (AMEX: CLDI) was released for 2025-03-31. The company reported revenue of $5.06 million for the quarter, compared to $6.75 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -25.03 percent.
